How Many Seres Therapeutics, Inc. (NASDAQ:MCRB)’s Analysts Are Bearish?

Seres Therapeutics, Inc. (NASDAQ:MCRB) Logo

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 2 analysts covering Seres Therapeutics (NASDAQ:MCRB), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Seres Therapeutics had 2 analyst reports since August 3, 2018 according to SRatingsIntel. On Friday, August 3 the stock rating was downgraded by Bank of America to “Underperform”. Below is a list of Seres Therapeutics, Inc. (NASDAQ:MCRB) latest ratings and price target changes.

22/10/2018 Broker: Chardan Capital Markets Rating: Buy New Target: $15 Initiates Coverage On
03/08/2018 Broker: Bank of America Old Rating: Neutral New Rating: Underperform Downgrade

The stock decreased 4.48% or $0.3 during the last trading session, reaching $6.39. About 77,703 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 26.54% since December 15, 2017 and is downtrending. It has underperformed by 26.54% the S&P500.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $261.07 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

More notable recent Seres Therapeutics, Inc. (NASDAQ:MCRB) news were published by: which released: “Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate – Business Wire” on November 07, 2017, also with their article: “Seres Therapeutics: This Time, Success? – Seeking Alpha” published on June 19, 2017, published: “Seres: Modest Revenue Potential For Early Drug Candidates – Seeking Alpha” on June 21, 2016. More interesting news about Seres Therapeutics, Inc. (NASDAQ:MCRB) were released by: and their article: “Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis – Business Wire” published on January 04, 2018 as well as‘s news article titled: “Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates –” with publication date: August 02, 2018.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.